Study reveals gene therapy may help in treating cardiac disease – The Siasat Daily
By daniellenierenberg
California: In a breakthrough study, researchers have found a potential treatment for life-threatening cardiac diseases by using gene therapy.
Danon disease is a very rare, life-threatening condition where the fundamental biological process of removing and recycling proteins does not work.
This impairment results in dysfunction of the heart, skeletal muscle, neurologic system, eyes, and liver. Most patients die or require heart transplants by the third decade of life.
In the study, which was published in Science Translational Medicine, researchers have identified a novel way to treat Danon disease using gene therapy.
Heart transplant is not always available for patients and does not treat the other organs affected in Danon disease. We knew we needed to find therapies specifically designed to address the underlying cause, said the lead researcher Eric Adler.
Danon disease is a result of mutations in the gene LAMP2. For nearly a decade, Adler and a team of researchers at UC San Diego Health have been working to determine whether gene therapy could provide a new treatment approach.
Gene therapy involves either replacing or repairing a gene that causes a medical problem or adding genes to help the body treat disease. In this case, Adler and the team focused on adding a specially designed gene that restores the LAMP2 function, resulting in improved cardiac and liver function.
We utilised mice that were a model for Danon disease and missing this specific LAMP gene. We applied gene therapy to a group of these mice and compared to mice that did not receive treatment, said Adler.
The mice that received gene therapy expressed positive results in heart, liver and muscle function. The hearts overall function of ejecting blood and relaxing improved, as did the bodys ability to degrade proteins and metabolism.
Danon disease is more common in males, and symptoms begin in early childhood or adolescence.
In many cases, the condition is inherited by a parent, typically the mother. We believe Danon disease is actually more common than we think, but it is often misdiagnosed, said Adler.
By utilising gene therapy, we were able to identify a possible new treatment approach other than a heart transplant. This study is a significant step for patients with Danon disease, Adler added.
Prior studies in Adlers lab have focused on using a patients skin cells to create stem cells. These stem cells were used to create a heart model, allowing researchers to study Danon disease at the cellular level.
The approach has provided new insight into the diseases pathology and led to the idea of using gene therapy. Our work is also proof that using stem cells to model diseases has great potential for helping develop new medicines, said Adler.
The next step, said Adler, is testing in patients with Danon disease. A Phase I clinical trial for safety and efficacy has begun.
This is the first trial using gene therapy to treat a genetic cardiac disorder and three patients are currently being treated, which means were that much closer to finding a cure for this terrible disease, and may be able to use similar methods to treat other diseases, said Adler.
Get the latest updates in Technology, Entertainment, Sports, Politics and Top Stories on WhatsApp & Telegram by subscribing to our channels. You can also download our app for Android and iOS.
Visit link:
Study reveals gene therapy may help in treating cardiac disease - The Siasat Daily
The therapeutic options are still insufficient – Bandera County Courier
By daniellenierenberg
How many sufferers are currently on the Covid 19 Charit stations, and what is the treatment of the patients who come to you?
We have on our Covid 19 ward currently has nine patients, including some who are doing reasonably well but cannot be well cared for at home, and those who are a little more serious and who need support from one to two liters of oxygen per minute. Some of them also have to be checked repeatedly to determine whether they need to be transferred to the intensive care unit and mechanically ventilated. And finally there are eleven ventilated patients in our Covid intensive care unit today.
When should ventilation be?
What is important is the respiratory rate, i.e. the frequency with which the patient breathes and the saturation of his blood with oxygen . We observe: How much oxygen do I give, how much is received? This is a good parameter for the extent of lung damage. The patient experiences exhaustion at a certain point, then we have to ventilate. Covid 19 has something very destructive to the lung cells.
[Die neuesten Entwicklungen und Hintergrnde zum Coronavirus knnen Siehier in unserem Newsblog mitverfolgen.]
If everything goes well, the situation will improve within three days, so that we can weave the patient, ie wean from the ventilator, but it can also take a week or two last. This type of ventilation is not enough for a subgroup, here we use a kind of replacement lung outside the body. All of this is not new territory for intensive care medicine, but it is very complex and personnel-intensive.
Sick every year 750. 000 People with pneumonia, 290. 000 from them to the hospital. So there is plenty of experience with pneumonia. What is special about the current situation?
If you look at the classic bacterial pneumonia, then come against the bacteria use antibiotics. In these cases, you can often see a black-and-white effect: seriously ill people quickly get well with medication. That is now different in the treatment of the Covid virus infection 19 Antibiotics play no role at first, they may come into play later with complications caused by bacteria. What we have so far against Covid 19 is insufficient.
Which drugs are used?
First there is an old preparation from HIV treatment, Kaletra, which contains the active substances against retroviruses lopinavir and retonavir contains. However, the effect and possible side effects have to be weighed here, because the agent can, for example, increase liver values. In the New England Journal of Medicine (NEJM), a paper from China has just appeared in which its use made no difference. However, there was only very late, namely twelve to 13 days after Beginning of the disease, therapy started.
Then there is a candidate from Ebola research, the active ingredient Remdesivir. According to the first findings, it seems to be rather effective, but of course the experiences are not endless. Studies are ongoing and you can use it as part of an individual healing attempt. However, it is currently difficult to get hold of the drug, it is not supplied in large quantities. It is very important that you can only have it within the framework of a formalized process. There is a narrow treatment window: the patient must be intubated, but he must not have circulatory failure.
What about the malaria drug hydroxychloroquine, about which a violent dispute has arisen between the virologists in France after a small, uncontrolled study?
Hydroxycloroquine appears with every new virus infection because it has a certain effectiveness. However, this active ingredient also has side effects, especially on the cardiac conduction system. It is therefore important to monitor the patient's ECG. A large randomized clinical trial of hydroxychloroquine is currently underway under the direction of the University Hospital in Tbingen.
What about clinical studies, science comes In view of the tense situation in everyday clinical practice, rightly so?
Yes, we will do better than a few years ago at EHEC! In the end, there were no really new insights. This is changing this time, we are closely networked, randomized clinical studies are being carried out that span several centers, and the procedures are being coordinated. Not everyone can do what they want. We have come together in competence networks. Physicians, large clinics and scientists from basic research have been working well together for years in the CAP network for pneumonia acquired outside the hospital, which was funded by the Federal Ministry of Research and is now working as a foundation. Large international clinical trials are now underway.
The French national research institution Inserm announced yesterday that its Aegis the substances Kaletra, Remedesvir and Hydrochloroquine, which we have just spoken about to be compared in a large international study called Discovery, the WHO launched the large-scale study Solidarity. Agents that are already being used against other diseases are being tested. How about the ACE2 inhibitor, of which there is currently a lot of talk ?
We have Access to the inhibitor that attaches to ACE2 and its associated protease and can thus block virus uptake into the cell, and we will also test it in a study. However, this ACE2 inhibitor has so far only proven its effectiveness in cell culture. The question remains whether and in what dose it works in humans. I know of a dozen other drug candidates whose investigation is planned as part of studies in our clinic. This also includes some experimental approaches that are used to block signaling pathways in the cell so that the virus cannot replicate, or in which stem cells are used. Another approach is to restore the tightness of the vessels. With severe pneumonia, there is water in the lungs where there used to be air. The lungs look white on the x-ray.
What about the idea , use blood plasma from people who have survived the disease to heal the sick?
This is obvious and is currently being pursued. If you think about it further, you could use antibody-based therapy. The cells that made the antibody in a previous patient are isolated beforehand and ultimately let them produce large amounts of antibody.
In addition to this search for new therapies Research on other questions is also important: In the BMBF-funded project PROGRESS-net, we have been dealing with the genetic differences between patients with severe pneumonia for some time. We want to understand why some of them have to go to intensive care later because they develop lung failure and possibly sepsis. And we want to be able to predict it.
What situation are we in now and how will it go on? Currently the therapeutic instruments are very modestly equipped. It is now the phase of science and clinical trials. However, unlike Italy at the moment, we have the chance not from Covid 19 to be overwhelmed if we test sensibly and know where we stand.
We are in a different situation from the plague in the Middle Ages, where people are were smart enough to use contact blocks, but the epidemic only came to a halt after there were no longer enough victims. We can hope that in the end a new therapeutic or a new vaccine will put an end to the spook.
Go here to see the original:
The therapeutic options are still insufficient - Bandera County Courier
VIDEO: Trump and Federal Coronavirus Task Force update nation on latest efforts to fight the pandemic – Honolulu Star-Advertiser
By daniellenierenberg
The Latest on the coronavirus pandemic, which has infected more than 307,200 people and killed more than 13,000. The COVID-19 illness causes mild or moderate symptoms in most people, but severe symptoms are more likely in the elderly or those with existing health problems. More than 92,000 people have recovered so far, mostly in China.
NEW YORK >> New York City hospitals are just 10 days from running out of really basic supplies, Mayor Bill de Blasio said late Sunday.
If we dont get the equipment, were literally going to lose lives, de Blasio told CNN.
De Blasio has called upon the federal government to boost the citys quickly dwindling supply of protective equipment. The city also faces a potentially deadly dearth of ventilators to treat those infected by the coronavirus.
Health care workers also warned of the worsening shortages, saying they were being asked to reuse and ration disposable masks and gloves.
New York City hospitals scrambled Sunday to accommodate a new swell of patients, dedicating new COVID-19 wings in their facilities. It remained extremely busy at Northwell hospitals, a spokesman said, adding their intensive care units were filling up.
A number of hospitals have reported that they are becoming overwhelmed, said Jonah Allon, a spokeswoman for Brooklyn Borough President Eric Adams.
TORONTO >> Canada says it wont attend the Olympics this summer, calling for a postponement for a year.
The Canadian Olympic Committee sent out a statement Sunday night saying its refusing to send a team to Tokyo unless the Games, which are scheduled to start on July 24, are pushed back by 12 months.
The COCs statement comes amid criticism of the International Olympic Committees response to the COVID-19 pandemic.
SEOUL >> South Korean low-cost airline Eastar Jet says it will shut down all flights, becoming the first South Korean carrier to do so amid a sharp decline in travel over the global coronavirus crisis.
The company on Monday said it will temporarily suspend its domestic flights from Tuesday to April 25 because of decreased demand.
Eastar, which had flown to various places in Asia and Russias Vladivostok, halted its last international routes earlier this month when Japan began enforcing 14-day quarantines on passengers arriving from South Korea.
South Korean carriers have been cutting back or suspending flights amid the global spread of COVID-19. Other budget carriers such as Air Seoul, Air Busan and TWay Air are currently operating only domestic flights after suspending their international services.
BEIJING >> Chinas National Health Commission on Monday reported 39 new cases of COVID-19, all of which it says are imported infections in recent arrivals from overseas.
For more than a week, the majority of mainland Chinas reported cases have been found in people coming from other countries, while community transmission inside the country has dwindled, according to the National Health Commission.
Seeking to prevent a resurgence of the virus, which first emerged late last year in central China, the government is imposing a strict quarantine on individuals entering the country.
Beginning Monday, all flights into Beijing will be diverted to one of 12 airports in other cities. Passengers must pass a health inspection in one of those cities before flying onward to the Chinese capital. They must then quarantine themselves in a hotel for 14 days at their own expense.
TOKYO >> Japan Prime Minister Shinzo Abe said Monday that a postponement of the Olympics is unavoidable if it cannot be held in a complete way due to the coronavirus impact.
He was commenting on the International Olympic Committee plan to examine the situation over the next few weeks and make a decision, which could include a postponement option.
Abe, speaking at a parliamentary session, ruled out a possibility of a cancellation.
Whether Japan can hold the Tokyo Games as planned on July 24 has been a major international concern as the COVID-19 pandemic has spread globally, especially hitting hard Europe and the U.S.
WELLINGTON, New Zealand >> New Zealand will go into a full lockdown for about four weeks, Prime Minister Jacinda Ardern announced on Monday.
She said the lockdown will begin in 48 hours time. People must stay at home and all non-essential businesses and activities cease.
The decision came as health officials announced another 36 confirmed cases of COVID-19, bringing the total to 102. Most of those cases have been traced to people returning from overseas but crucially two of the cases could not be traced and officials believe are evidence of a local outbreak.
Ardern said there would be an unprecedented level of economic and social disruption as a result of the lockdown.
I do not underestimate what Im asking New Zealanders to do, she said. It is huge, and I know it will feel daunting. But she said it was important to act early to save tens of thousands of lives.
There have been no deaths due to the coronavirus in New Zealand, which has a population of 5 million.
WASHINGTON >> The Senate has refused to advance the coronavirus rescue package in a procedural vote with Democrats rejecting a draft from Republicans and pushing for more aid for workers.
Negotiations are expected to continue into the evening Sunday.
Senate Majority Leader Mitch McConnell has urged senators to signal to the public that were ready to get this job done. He wants passage by Monday.
But Democrats have resisted, arguing the nearly $1.4 trillion measure needs to bolster aid and put limits on how businesses can use the emergency dollars.
More voting is possible.
NEW YORK >> Futures for U.S. stocks fell sharply at the start of trading Sunday as investors watch to see if Congress can agree on a huge rescue package to try to stem the impact of the coronavirus outbreak.
Futures for the S&P 500 fell by 5%, triggering a halt in futures trading.
Wall Street is coming off its worst week since 2008. The S&P 500 fell 15% as large swaths of the U.S. economy shut down and investors waited for Washington to deliver financial support for American workers and battered industries such as airlines and hotels. Democrats have argued the package was tilted toward corporations rather than workers and health care providers, so negotiations are ongoing.
Oil prices also tumbled as the broad global economic slowdown threatens demand for energy. The price of U.S. oil fell 6% to $21.26 a barrel, while the international benchmark dropped 7% to $25.10
WASHINGTON >> President Donald Trump says hes ordered the Federal Emergency Management Agency to ship mobile hospital centers to the hard-hit states of Washington, California and New York amid the coronavirus pandemic. For New York, that would mean another 1,000 hospital beds.
Trump is also revealing for the first time the number of respirators and other personal protective equipment sent to the hard-hit states by the federal government. It comes as state and local leaders have appealed on the federal government to provide far more, and as Trump has held off on using his fully authorities under the Defense Production Act to marshal the private sectors capabilities.
Trump says its up to states to try to get the materials first. He says: Were sort of a backup for states.
Trump says hes also giving governors in those three states in calling up their national guard, keeping it under local control but providing federal funding.
The U.S. Ambassador to the west African nation of Burkina Faso has become the most senior American diplomat known to have tested positive for the coronavirus.
Ambassador Andrew Young announced his status on his Twitter account on Sunday, saying he had received a positive test for COVID-19, which was later confirmed by the State Department in Washington. Young said the embassy had taken steps to quarantine affected community members.
Officials and diplomats in Burkina Faso has been hard hit by the virus with several government ministers testing positive, including the minister of mining, the minister of interior and education. The Italian ambassador has also contracted the virus.
Several other U.S. diplomats and State Department employees have also tested positive for the virus, including at least one who works at an annex to the agencys main headquarters in Washington and at least one in Kingston, Jamaica and Geneva, Switzerland. Numerous others in other locations have gone into self-isolation after being exposed to people who have tested positive.
CAIRO >> Egypts President Abdel-Fattah el Sissi appealed to his people to help stem the spread of the coronavirus through staying at home and practicing social distancing, as the confirmed cases of the virus reached 327 and 15 deaths.
He warned that that numbers of the infected could be in thousands within days, if people did not take the virus seriously.
Help us, Egyptians! he appealed to his people. We want more commitment and discipline for the next two weeks in order to stem the spread of the coronavirus in Egypt.
He urged Egypts more than 100 million people to take the spread of virus very seriously.
He said his government have taken simple measures including the closure of schools and universities, a nightly curfew on shops, restaurants and other businesses in efforts to minimize interaction between people. He also thanked doctors and health workers as heroes who are fighting a battle like a war.
Egypts health ministry added 33 more confirmed cases of the coronavirus and four new deaths, bringing the total number to 327 and 14 deaths. It said over 50 were discharged from the quarantine after their recovery. The military earlier Sunday reported the death of a major general while taking part in sterilization efforts.
CAIRO >> Egypts military said a senior officer died Sunday following his infection from the coronavirus.
The military said in a statement that Major General Khaled Shaltout was infected while participating in sterilization which the military has been carrying out across the country.
The military said it has sterilized and disinfected public institutions and several squares in the capital, Cairo and other cities, to stem the spread of the coronavirus.
Military spokesman Tamer el-Refai Saturday posted footage on social media showing military personal in protective gear and equipment while disinfecting the Tahrir square, the epicenter of the 2011 uprising, and the metro station there.
Shaltout was the highest official infected by the virus to date in Egypt, which has around 300 cases and 10 deaths.
BATON ROUGE, La. >> Gov. John Bel Edwards has issued a statewide stay at home directive, ordering all 4.6 million people in Louisiana to stay at home starting at 5 p.m. on Monday unless theyre performing an essential task like getting food or medicine.
Workers in grocery stores, pharmacies, doctors offices and other critical infrastructure are exempt from the governors directive.
The bottom line is we are in a race against time when it comes to this coronavirus and its rapid spread in Louisiana, Edwards said Sunday.
New York, California, Illinois and some cities have issued similar shelter in place or stay at home orders in the last few days. New Orleans Mayor LaToya Cantrell had issued a similar order for that city two days ago.
As of Sunday, coronavirus infections in Louisiana have climbed to more than 830. Twenty people in the state have died of COVID-19, state health officials said.
BOUNTIFUL, Utah >> Utah has reported its first death related to COVID-19 a man over the age of 60 who had underlying health problems.
State health and hospital officials said Sunday that the unidentified man from Davis County had been at Lakeview Hospital in Bountiful for two days before his death.
The man tested positive for the coronavirus on Saturday.
Health officials are working to identify and contact anyone who may have been in close contact with him. His family notified the hospital of the possibility of him having COVID-19 before his arrival.
The hospitals CEO says workers met him in the parking lot in full protective gear, limiting possible exposure.
ISTANBUL >> Nine more people have died in Turkey from the coronavirus, bringing the countrys death toll to 30.
Health Minister Fahrettin Koca said on Twitter that 289 people tested positive for COVID-19 Sunday. The total number of confirmed cases in the country is now at least 1,236.
PARIS >> Frances Parliament has adopted a bill allowing the government to declare a state of health emergency meant to better fight the coronavirus epidemic in the country.
The measure voted Sunday allows the government to issue decrees that curtail temporarily freedoms, including restrictions on movements, trade, entrepreneurship and gatherings. It also enables the government to requisition necessary goods and services to fight against a health disaster.
The state of heath emergency is yet to be formally declared by President Emmanuel Macrons government during a Cabinet meeting.
The measure was needed to provide legal basis to ensure the continuity of current emergency measures in the country and the democratic functioning of the state.
The bill also includes the postponing of nationwide municipal elections initially due to take place on Sunday and a package of economic measures to support workers and businesses hardly hit by the crisis.
French health authorities have reported 16,018 confirmed cases of COVID-19, including 674 people who have died.
WASHINGTON >> Republican Sen. Rand Paul of Kentucky is the first U.S. senator to test positive for COVID-19, the infection caused by the coronavirus.
Thats according to a tweet from the senator, who is a top ally of President Donald Trump.
The senator is feeling fine, the tweet said. He is asymptomatic, and in quarantine.
He was not aware of any direct contact with any infected person, the tweet said.
This comes shortly after the nations capital announced its second death to coronavirus.
BERLIN >> German Chancellor Angela Merkel has gone into quarantine after being informed that a doctor who administered a vaccine to her has tested positive for the coronavirus.
Merkels spokesman said the German chancellor was informed about the doctors test shortly after holding a news conference Sunday announcing new measures to curb the spread of the virus.
Her spokesman, Steffen Seibert, said Merkel had received a precautionary vaccine Friday against pneumococcal infection.
Seibert said in a statement that Merkel would undergo regular tests in the coming days and continue with her work from home for the time being.
Original post:
VIDEO: Trump and Federal Coronavirus Task Force update nation on latest efforts to fight the pandemic - Honolulu Star-Advertiser
The Sound of Science – ‘Nina Tandon’ | WNIJ and WNIU – WNIJ and WNIU
By daniellenierenberg
The Sound of Science - 'Nina Tandon' (March 20, 2020)
Alexis: Welcome to the Sound of Science on WNIJ. Im Alexis from NIUSTEM Outreach.
Idalia: And Im Idalia. Todaywe will be discussing American biomedical engineer, Nina Tandon.
Alexis:Dr. Tandongrew upin New York City with two siblings with visual impairments. Its no wonder why she chose toinvestigatethe electrical currents that underline the nervous system.
Idalia:As a kid, she often took apart electronics to try to understand them from the inside out.
Alexis:Tandon went on to study Biomedical Engineering and earned her PhD from Columbia. She focused her research on studying electrical signals in engineered tissues, such as cardiac, skin, bone, and neural tissues.
Idalia:Her studies in both bioengineering and business came together as she and a colleague created EpiBone, the worlds first company to grow living human bones for skeletal reconstruction. EpiBoneuses stem cells from patients in need of new bones to produce skeletal structures based on each individual DNA profile.This decreases rejection, simplifies surgeries, and shortens recovery time.
Alexis:SinceDr. Tandon madesuch a giant leap for bioengineering innovation, its clear why she received awards such as "One of the 100 Most Creative People in Business" byFast Companyand "Global Thinker" byForeignPolicy.
Idalia:She is an inspirational woman who completed what was once thought to be impossible.Yet, sheis far from being done.Her companys bioengineered tissues are being used for testing pharmaceuticals without using rats or humans. She says Our process is essentially transforming biotechnology and pharmacology into information technology, helping us discover and evaluate drugs faster, more cheaply and more effectively.
Alexis: Tune in next week where wego into detail aboutmore women in STEM.This has been the Sound of Science on WNIJ.
Idalia: Where you learn something new every day.
See the original post here:
The Sound of Science - 'Nina Tandon' | WNIJ and WNIU - WNIJ and WNIU
Ready To Use Autologous Stem Cell Based Therapies Market size and forecast, 2019-2020 – Packaging News 24
By daniellenierenberg
With having published myriads of reports, Autologous Stem Cell Based Therapies Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.
In this new business intelligence report, Autologous Stem Cell Based Therapies Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Autologous Stem Cell Based Therapies market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Autologous Stem Cell Based Therapies market.
Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2278181&source=atm
The Autologous Stem Cell Based Therapies market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.
The key players covered in this studyRegeneusMesoblastPluristem Therapeutics IncU.S. STEM CELL, INC.Brainstorm Cell TherapeuticsTigenixMed cell Europe
Market segment by Type, the product can be split intoEmbryonic Stem CellResident Cardiac Stem CellsUmbilical Cord Blood Stem Cells
Market segment by Application, split intoNeurodegenerative DisordersAutoimmune DiseasesCardiovascular Diseases
Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America
The study objectives of this report are:To analyze global Autologous Stem Cell Based Therapies status, future forecast, growth opportunity, key market and key players.To present the Autologous Stem Cell Based Therapies development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Autologous Stem Cell Based Therapies are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2278181&source=atm
What does the Autologous Stem Cell Based Therapies market report contain?
Readers can get the answers of the following questions while going through the Autologous Stem Cell Based Therapies market report:
And many more
You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2278181&licType=S&source=atm
For More Information Kindly Contact:
marketresearchhub.com
Mr. Nachiket Ghumare,
90 State Street,
Albany NY,
United States 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: [emailprotected]
Autologous Stem Cell Based Therapies Market 2020: Potential Growth, Challenges, Attractive Valuation | Key Players: Anterogen, Holostem Advanced…
By daniellenierenberg
Global Autologous Stem Cell Based Therapies Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Autologous Stem Cell Based Therapies industry, focusing on the main regions and the main countries (United States, Europe, Japan and China).
Market Segmentations: Global Autologous Stem Cell Based Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.
Based on type, report split into Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells.
Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases.
The report introduces Autologous Stem Cell Based Therapies basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Autologous Stem Cell Based Therapies Market for the coming few years have also been included in the report.
Autologous Stem Cell Based Therapies Market landscape and market scenario includes:
The Autologous Stem Cell Based Therapies industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.
ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/4403641/autologous-stem-cell-based-therapies-industry-mark
CHAPTERS COVERED IN THIS REPORT ARE AS FOLLOW:
Get Special Discount Up To 50%, https://inforgrowth.com/discount/4403641/autologous-stem-cell-based-therapies-industry-mark
FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com
Go here to see the original:
Autologous Stem Cell Based Therapies Market 2020: Potential Growth, Challenges, Attractive Valuation | Key Players: Anterogen, Holostem Advanced...
NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space – Business Wire
By daniellenierenberg
SEATTLE--(BUSINESS WIRE)--NanoSurface Biomedical announced today that it has executed an exclusive IP license agreement related to innovative heart-on-chip technology developed by researchers at the University of Washington (UW). An experimental system built from the same heart-on-chip technology was launched into space on Friday, March 6, 2020 at 11:50 PM EST aboard SpaceX's 20th resupply mission to the International Space Station (ISS) as part of the Tissue Chips in Space initiative conducted in partnership between the National Center for Advancing Translational Sciences (NCATS) and the ISS U.S. National Laboratory (ISS National Lab). NanoSurface will commercialize the heart-on-chip platform for use by pharmaceutical companies in preclinical drug development.
The heart-on-chip system will spend 30 days aboard the ISS as part of a series of experiments intended to study the effects of microgravity on human cells and tissues. In space we are using the heart-on-chip system in microgravity conditions to help improve our understanding of the aging process and cardiac biology, but this heart-on-chip system also has enormous potential for accelerating the discovery of new medicines back here on Earth, said Deok-Ho Kim, an Associate Professor of biomedical engineering and medicine at Johns Hopkins University, the principal investigator for the heart-on-chip experiment aboard the ISS, and the scientific founder of NanoSurface Bio.
The heart-on-chip platform uses three-dimensional engineered cardiac tissues (3D ECTs) grown from human cardiomyocytes, or beating heart cells, derived from induced pluripotent stem cells (iPSCs). As the 3D ECTs beat, researchers can measure the amount of force generated by each contraction, and then evaluate how that force changes after treating the tissues with candidate drugs. 3D ECTs can be made from cells from either healthy individuals or individuals with diseases, offering great promise in predictive preclinical testing of candidate drugs for safety and efficacy.
I am incredibly excited that the talented team at NanoSurface will be carrying this technology forward for use in the drug development industry, said Nathan Sniadecki, one of the inventors of the heart-on-chip technology and a professor of mechanical engineering at UW. Last year, Professor Sniadecki joined NanoSurfaces board of scientific advisors to guide the commercial development of the technology.
NanoSurface Bios execution of this exclusive license adds significant value to the portfolio of IP it has already licensed from researchers at UW. It is well recognized that the drug development process is extremely slow and expensive. At NanoSurface we are eager to develop technologies that enable the use of human iPSC-derived cells and tissues in preclinical drug development, ultimately leading to better prediction of how drugs will affect patients in the clinic, lowering costs, and speeding life-saving medicines to market, said NanoSurface CEO Michael Cho.
About NanoSurface Biomedical
NanoSurface Biomedical is a biotechnology company based in Seattle, WA that develops stem cell-based assay technologies to accelerate drug development. NanoSurfaces structurally matured cardiac tissue models, assay instruments, and discovery services leverage human stem cell technology to help pharmaceutical companies predictively assess the safety and efficacy of candidate drugs early during preclinical development. NanoSurfaces mission is to help bring life-saving medicines to market in less time and at lower cost. To learn more, visit http://www.nanosurfacebio.com.
Read the original:
NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space - Business Wire
A new therapeutic approach against COVID-19 Pneumonia – Institute for Ethics and Emerging Technologies
By daniellenierenberg
The novel coronavirus disease 2019 (COVID-19) has grown to become a global public health emergency. Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the severe cases. A new study offers a promising pathway for developing such a treatment.
The new approach involves intravenous transplantation of mesenchymal stem cells (MSCs) into the patients. It was successfully tested in 7 COVID-19 patients, in Beijing YouAn Hospital, Capital Medical University, China. The results are published in the scientific journal Aging and Disease, entitled "Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia".
http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml
The study was conducted by a team led by Dr. Robert Chunhua Zhao, with Shanghai University and Chinese Academy of Medical Sciences & Peking Union Medical College, China.
Moreover the study was reviewed by a scientific committee of the International Society on Aging and Disease (ISOAD) and the recently established UNESCO-affiliated committee on Anti-Aging and Disease Prevention http://www.aginganddisease.org/article/2020/2152-5250/ad-11-1-212.shtml
Based on the 14 days observation, MSCs could cure or significantly improve the functional outcomes of all the seven tested patients without observed adverse effects, contrary to 3 controls. The pulmonary function and symptoms of these seven patients were significantly improved after MSC transplantation. Among them, one severe and two common patients recovered and were discharged in 10 days after the treatment. The improvement was particularly dramatic for an elderly (65 y.o.) male patient in severe critical condition. All of his primary and secondary outcomes improved: the inflammation status, the oxygen saturation, and the functional biochemical indicators returned to normal reference values in 2~4 days after the treatment.
The presented evidence suggests that the therapeutic effects are based on the immunomodulatory capacity of mesenchymal stem cells (restoring the balance of the immune system). The coronavirus infection can stimulate a terrible cytokine storm in the lung, disrupting the balance of cytokines (signaling molecules of the immune system) such as IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A and TNF cytokines, followed by the edema, dysfunction of the air exchange, acute respiratory distress syndrome, acute cardiac injury and the secondary infection, which may lead to death. The bone-marrow derived MSCs could inhibit the over-activation of the immune system and promote endogenous repair by improving the microenvironment, thus they could represent a safe and effective treatment for patients with COVID-19 pneumonia, especially for the patients in critically severe conditions. A larger validation study is required and is already underway, yet the initial results are encouraging.
Notably, the coronavirus-infected pneumonia is more likely to affect older individuals, especially older males, with comorbidities, resulting in their severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In other words, aging appears to be the main risk factor for bad outcomes. However, the cure essentially depends on the patient's own immune system. When the overactivated immune system kills the virus, it produces a large number of inflammatory factors, leading to the severe cytokine storms. This suggests that the main reason for the organs damage may be the virus-induced cytokine storm. Older subjects may be much easier to be affected due to immunosenescence. The study showed remarkable recovery of the elderly patients thanks to restoring their immune function.
Thus, the study may have a broader significance, even beyond the treatment of the severe coronavirus disease. This study exemplifies that the general therapeutic improvement of the immune system in the elderly can improve outcome and survival, which may have more general relevance for other aging-related communicable diseases. Thus, this study may inspire and pave the way for further promising directions to investigate the connection between aging and disease, and to treat both communicable and non-communicable aging-related diseases.
The Romanian journalist Laura tefnu spoke with Dr. Ilia Stambler about the broader implications of this research. Ilia Stambler is a co-author in this study who was involved in the study review, interpretation and discussion. He serves as the Outreach Coordinator of the International Society on Aging and Disease (ISOAD) and Director of Research and Development at Shmuel Harofe Geriatric Medical Center in Israel.
Q: How does it feel to be part of the team which discovered a groundbreaking treatment for what is currently considered one of the biggest global challenges?
A: I feel very honored to be included in this extended international team. I hope this team continues its work that will also involve additional collaborations.
Q: As a researcher, what did you find most interesting about this novel coronavirus? What seems most threatening about this new virus?
A: The spreading ability of this virus is relatively high and it has the capacity to affect the entire global population. This is what makes this virus a particularly strong concern for global public health. The social effects of this epidemic are also of great importance. In a sense, this virus is testing the strength of our public health systems. Will the immunity of our public healthcare be strong enough to contain it? I hope it is.
Q: Did the discovery of this groundbreaking new therapeutic approach make you more optimistic (when it comes to containing and limiting the damage of Covid-19)? In which sense (where was your optimism before the discovery)?
A: I was optimistic before, as I believe that, same as for many infectious diseases in the past, also for this disease, effective therapeutic and preventive measures will be found and used. This work further increased my optimism. Of course, this is an initial study, and this is only one of the potential means in the therapeutic, preventive and hygienic arsenal. More research and confirmation will be needed. Yet, even at this stage, the clear positive result of this study shows that it is indeed possible to improve the outcomes for COVID-19 patients even in severe conditions. Moreover, it gives more hope that effective treatments can be sought and found also for other aging-related infectious diseases and conditions.
Q: Is there an explanation regarding the reasons why Covid-19 seems to pardon children and affects the most elder individuals, especially men?
A: There is yet no clear or fully agreed explanation. But a plausible cause may be due to the so called immuno-senescence phenomenon, or the inability of the aging immune system to cope with new threats and restore the immune balance following the infection. In men the immuno-senescence effects are often more strongly present than in women. Thus, aging appears to be the main risk factor for this disease and if we really wish to defeat this epidemic, we need to address this main risk factor, in other words, we need to therapeutically intervene and ameliorate the degenerative aging process. The proposed mesenchymal stem cell therapy shows the so-called immuno-modulation effects or the ability to generally improve the immune system, help restore the immune balance after disturbances, especially for the elderly. And this can be the more general explanation for its effects against the aging-related COVID-19 pneumonia, as well as potentially other aging-related diseases.
Q: How did you manage to find so fast a treatment that is responding so well?
A: The mesenchymal stem cell treatment has been researched and developed by Dr. Zhao and his team for many years, and indicated positive effects for multiple health conditions. It is exactly because of the common and critical role of the immune system impairment in all these conditions, that the treatment developed by Dr. Zhaos team was already in place and could be immediately used also for this condition dependent on the immune function. Moreover, the success of this therapy against COVID-19 can further boost the research and therapy of other immunity-dependent health conditions and diseases, especially aging-related diseases, due to the common mechanisms of action.
Q: How may this discovery change the game?
A: Unlike other public health measures, like quarantine and hygiene, that can be very quickly applied, the research, development, regulatory approval and application of new therapies is a much slower process. So we should first of all apply the public health measures to contain the epidemic. But the hope is that this therapy will undergo further research and validation as soon as possible, and in case of validated efficacy and safety, will be used in as many patients who need it as possible, as soon as possible. That is exactly why we need to accelerate the research, development and application of promising new therapies. When the new therapy enters wide clinical practice, there are grounds to believe it can improve the health and even save the lives of many patients, not only suffering from COVID-19, but also other conditions.
Q: Which was the response/reaction of authorities after you published the results of your research?
A: The outreach to the authorities in several countries has only started. Moreover, the study is only initial and it is too early to make policy recommendations. A larger validation study is required. Yet, if there is even a slight possibility this could become a life-saving therapy for COVID-19 patients and others, this opportunity should not be missed by the decision makers.
Q: Some treatments are more expensive than others. Will the treatment you discovered be accessible to people, or the cost for producing it will limit its accessibility?
A: The cells for this treatment can be mass produced and can be rather affordable. Of course, the actual price will depend both on the scale of production and pricing policies. And this is already a question that goes beyond pure technology, but becomes a question about the social means to make new therapies available to all. This should also be a crucial part of the public discussion about the social need to promote the rapid research and development as well as broad application of new therapies that are proven to be safe and effective.
Q: Which are the best measures a country can take to limit the spread and the consequences of the novel coronavirus?
The usual quarantine and public hygiene measures are the most feasible and effective: minimization of large gatherings, minimization of travel, cleanliness. We should hope and work for new effective therapies to arrive as soon as possible. But so far public health measures are the most effective and feasible.
Ilia Stambler is an IEET Affiliate Scholar. He completed his PhD degree at the Department of Science, Technology and Society, Bar-Ilan University. His thesis subject, and his main interest, is the History of Life-extensionism in the 20th Century.
Read the original:
A new therapeutic approach against COVID-19 Pneumonia - Institute for Ethics and Emerging Technologies
Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS | DNA RNA and Cells | News Channels – PipelineReview.com
By daniellenierenberg
DetailsCategory: DNA RNA and CellsPublished on Wednesday, 11 March 2020 09:50Hits: 179
-Cooperation in Product Development for Innovative Cardiac Regenerative Medicine-
March 10, 2020 I Tokyo-based Heartseed Inc. (Heartseed), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL HOLDINGS CORPORATION (MEDIPAL) today announced that they have entered into a capital and business alliance.
In conjunction with the alliance, MEDIPAL will acquire an equity stake in Heartseed. In addition, MEDIPAL and its wholly owned subsidiary SPLine Corporation (SPLine) will begin collaborative research with Heartseed on the logistics of Heartseeds clinical trial supplies.
Purpose of the Alliance
Heartseed is developing HS-001, allogeneic iPSC-derived cardiomyocyte spheroids for severe heart failure, which currently has no effective treatment other than heart transplantation. In preparation for the initiation of its clinical trial, Heartseed will outsource its manufacturing to Nikon CeLL innovation Co., Ltd., and are discussing transport of the cardiomyocyte spheroids with MEDIPAL.
MEDIPAL has established a distribution system in compliance with Japanese Good Distribution Practice (GDP) guidelines. MEDIPAL is a pioneer in logistics services in the growing field of regenerative medicine, and has an extensive track record to support development of regenerative medicine products and to build a logistics system for them using its ultra-low temperature transport system.
In this alliance, MEDIPAL will contribute to the improvement of patient care by promoting development of Heartseeds innovative products from the clinical trial stage with its experience and expertise in the distribution of regenerative medicine products.
Comment from Heartseed CEO Keiichi Fukuda, MD, PhD, FACC
The iPSC-derived cardiomyocyte spheroids we are developing are unique in the mechanism that cardiomyocytes are strengthened by turning them into microtissues. The spheroids will be retained and engrafted with the ventricular myocardium for a long-term and are expected to contribute sustained direct ventricular contraction (remuscularization). It is completely
different from conventional treatment methods. To deliver the treatment to patients, logistical considerations are also important, and we are pleased to partner with MEDIPAL, which has an extensive track record in distribution of cellular medicines.
Comment from MEDIPAL Representative Director, President and CEO Shuichi
Watanabe
Their investigational agent has the potential to be an innovative treatment option for patients with severe heart failure. Promoting the development and stable supply of specialty pharmaceuticals is our mission, based on MEDIPALs management philosophy of
contributing to peoples health and the advancement of society through the creation of value in distribution. In this alliance, SPLine, which performs logistical planning for specialty pharmaceuticals, will be involved from the clinical trial stage, and will also work with us in creating a distribution system to ensure safe and reliable delivery of the product to patients after its launch.
Development of HS-001
Heartseed has allogeneic iPSC-derived highly purified ventricular-specific cardiomyocyte spheroids (HS-001) as its lead pipeline candidate, and is conducting research and development for the early commercialization of cardiac regenerative medicine using iPSCs supplied by the Center for iPS Cell Research and Application (CiRA) at Kyoto University. HS-001 is the produced by differentiating into ventricular-specific cardiomyocytes from iPSCs with the most frequent human leukocyte antigen (HLA) type1 in Japanese people, and removing undifferentiated iPSCs and non-cardiomyocytes to achieve high purity. To improve the engraftment rate, these cardiomyocytes are formed into spheroids in which approximately 1,000 cardiomyocytes are aggregated.
Since 2016, Heartseed has had more than 10 meetings with the Pharmaceuticals and Medical Devices Agency (PMDA), with discussions mainly focused on details of nonclinical safety studies, manufacturing processes, and quality management that are required for initiating clinical trials. Heartseed is currently conducting the nonclinical safety studies under Good Laboratory Practice (GLP)2 standards under the agreement of the PMDA on their designs.
Prior to the company-sponsored clinical trials, investigator-initiated clinical trial plan of HS-001 at Keio University had been under review by the Keio University Certified Special Committee for Regenerative Medicine since May 2019 and was approved in February 2020. This plan will be submitted to the Health Science Council of Ministry of Health, Labor and Welfare after going through established procedures in Keio University Hospital. For 90 days from its submission to the Council, the plan will be examined for conformance with the regenerative medicine provision standards. If conformance is verified, Keio University will be notified and may then begin clinical research.
1. HLA type:White blood cell type, immune rejection is less likely when the HLA type matches.
2. GLP(Good Laboratory Practice):Standards for conducting studies to assess drug safety. These standards should be followed when conducting safety studies using animals in the preclinical stage.
Summary of HS-001
Severe heart failure, particularly heart failure with reduced ejection fraction
About Heartseed Inc.
About MEDIPAL HOLDINGS CORPORATION
As a holding company, MEDIPAL controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and
OTC Pharmaceutical Wholesale Business; and the Animal Health Products and
Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.
About SPLine Corporation
3.ALC: Area Logistics Center
4. FLC: Front Logistics Center
SOURCE: Heartseed
3D Cardiac Mapping Systems Market Key Vendors, Analysis by Growth and Revolutionary Opportunities by 2028 – 3rd Watch News
By daniellenierenberg
Global 3D Cardiac Mapping Systems Market: Overview
Cardiac mapping is a special type of technique which helps in gathering and displaying the information from cardiac electrograms. Such technique is mainly used in the diagnosis of heart rhythms. Therefore, cardiac mapping technique has gained immense popularity in case of arrhythmia. The cardiac mapping procedure involves the percutaneous insertion of catheter into the heart chamber and recording the cardiac electrograms sequentially. Such procedure helps in correlating the cardiac anatomy with the electrograms. The latest 3D cardiac mapping systems provide the three dimensional model of hearts chamber, which further helps in tracking the exact location of the catheter. Such advantages are majorly driving the global 3D cardiac mapping systems market.
Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5324
From the perspective of technology, the global 3D cardiac mapping systems market is segmented into basket catheter mapping, electroanatomical mapping, and real-time positional management (Cardiac pathways) EP system. Among these segments, electroanatomical mapping segment accounts for the maximum share in the global 3D cardiac mapping systems market. This mapping are extensively used in several healthcare industry due to its potential in increasing the safety, accuracy, and efficiency of catheter. A research report by TMR Research (TMR) thoroughly explains the new growth opportunities in the global 3D cardiac mapping systems market. Additionally, the report also provides a comprehensive analysis of the markets competitive landscape.
Global 3D Cardiac Mapping Systems Market: Notable Developments
Some of the recent developments are contouring the shape of the global 3D cardiac mapping systems market in a big way:
Key players operating in the global 3D cardiac mapping systems market include BioScience Webster, Boston Scientific Corporation, and Abbott.
Global 3D Cardiac Mapping Systems Market: Key Growth Drivers
Rising Number of Patients with Cardiac Disorders and Arrhythmia Fillips Market
The global 3D cardiac mapping systems market has grown steadily over the years, owing to the convenience it provides to the patients with heart problem. Growing number of people with cardiovascular diseases and rising cases of arrhythmia are the major factors fueling growth in the global 3D cardiac mapping systems market. Along with this, increasing pressure for reducing diagnosis errors and rapidly rising healthcare expenditure are also responsible for boosting the global 3D cardiac mapping systems market. However, above all such factors, the global 3D cardiac mapping systems market is majorly fueled by the accuracy and patient safety provided through real-time monitoring. Such 3D cardiac mapping systems are mainly designed to improve the resolution. This system also helps in gaining prompt of cardiac activation maps. All such advantages are also providing impetus to the growth of the global 3D cardiac mapping systems market.
Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5324
Furthermore, rising ageing population who are prone to heart-attack and several chronic heart disorders and increasing diagnosis rate of cardiac illness are the factors stoking demand in the global 3D cardiac mapping systems market. Moreover, this 3D cardiac mapping helps in reducing the diagnosis time. Such factor is also contributing to the growth of the global 3D cardiac mapping systems market.
Global 3D Cardiac Mapping Systems Market: Regional Outlook
On the regional front, North America is leading the global 3D cardiac mapping systems market as the region has seen rapid growth in healthcare industry. Along with this, increasing prevalence of heart attacks, rising healthcare expenditure, and burgeoning population is also responsible for fueling growth in the 3D cardiac mapping systems market in this region.
About TMR Research:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space – Yahoo Finance
By daniellenierenberg
NanoSurface Biomedical announced today that it has executed an exclusive IP license agreement related to innovative heart-on-chip technology developed by researchers at the University of Washington (UW). An experimental system built from the same heart-on-chip technology was launched into space on Friday, March 6, 2020 at 11:50 PM EST aboard SpaceX's 20th resupply mission to the International Space Station (ISS) as part of the Tissue Chips in Space initiative conducted in partnership between the National Center for Advancing Translational Sciences (NCATS) and the ISS U.S. National Laboratory (ISS National Lab). NanoSurface will commercialize the heart-on-chip platform for use by pharmaceutical companies in preclinical drug development.
The heart-on-chip system will spend 30 days aboard the ISS as part of a series of experiments intended to study the effects of microgravity on human cells and tissues. "In space we are using the heart-on-chip system in microgravity conditions to help improve our understanding of the aging process and cardiac biology, but this heart-on-chip system also has enormous potential for accelerating the discovery of new medicines back here on Earth," said Deok-Ho Kim, an Associate Professor of biomedical engineering and medicine at Johns Hopkins University, the principal investigator for the heart-on-chip experiment aboard the ISS, and the scientific founder of NanoSurface Bio.
The heart-on-chip platform uses three-dimensional engineered cardiac tissues (3D ECTs) grown from human cardiomyocytes, or beating heart cells, derived from induced pluripotent stem cells (iPSCs). As the 3D ECTs beat, researchers can measure the amount of force generated by each contraction, and then evaluate how that force changes after treating the tissues with candidate drugs. 3D ECTs can be made from cells from either healthy individuals or individuals with diseases, offering great promise in predictive preclinical testing of candidate drugs for safety and efficacy.
"I am incredibly excited that the talented team at NanoSurface will be carrying this technology forward for use in the drug development industry," said Nathan Sniadecki, one of the inventors of the heart-on-chip technology and a professor of mechanical engineering at UW. Last year, Professor Sniadecki joined NanoSurfaces board of scientific advisors to guide the commercial development of the technology.
NanoSurface Bios execution of this exclusive license adds significant value to the portfolio of IP it has already licensed from researchers at UW. "It is well recognized that the drug development process is extremely slow and expensive. At NanoSurface we are eager to develop technologies that enable the use of human iPSC-derived cells and tissues in preclinical drug development, ultimately leading to better prediction of how drugs will affect patients in the clinic, lowering costs, and speeding life-saving medicines to market," said NanoSurface CEO Michael Cho.
About NanoSurface Biomedical
NanoSurface Biomedical is a biotechnology company based in Seattle, WA that develops stem cell-based assay technologies to accelerate drug development. NanoSurfaces structurally matured cardiac tissue models, assay instruments, and discovery services leverage human stem cell technology to help pharmaceutical companies predictively assess the safety and efficacy of candidate drugs early during preclinical development. NanoSurfaces mission is to help bring life-saving medicines to market in less time and at lower cost. To learn more, visit http://www.nanosurfacebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200309005703/en/
Contacts
NanoSurface BiomedicalDirector of Sales & Marketing: Heejoon Choi, 800-913-4403 x702heejoon@nanosurfacebio.com
Continue reading here:
NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space - Yahoo Finance
Stem Cell Assay Market Competitive Analysis and Forecast 2017-2025 – Monroe Scoop
By daniellenierenberg
Stem Cell Assay Market: Snapshot
Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues and tumors, wherein their toxicity, impurity, and other aspects are studied.
With the growing number of successful stem cell therapy treatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.
Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40
Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.
Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.
Global Stem Cell Assay Market: Overview
The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.
The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.
Global Stem Cell Assay Market: Key Market Segments
For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.
In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.
The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.
Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40
Global Stem Cell Assay Market: Regional Analysis
Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.
Global Stem Cell Assay Market: Vendor Landscape
A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.
Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).
About TMR Research:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Read more:
Stem Cell Assay Market Competitive Analysis and Forecast 2017-2025 - Monroe Scoop
The Aussie Biotech Companies Trying To Make A Buck From Coronavirus – D’Marge
By daniellenierenberg
This story originally appeared onStockhead.
As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the c word. Were talking of course about the coronavirus COVID-19 but sadly not another c word: cure.
Or not yet.
According to broker Morgans daily tally, the virulent bug has so far infected 95,332 people, with 38,564 current cases (6,883 of them critical).
Of the remaining 56,768 cases with an outcome, 53,483 recovered and 6,883 achieved a definitive performance indicator. They died.
Okay, a circa 7 per cent mortality rate or even a 1 or 2 per cent rate is nothing to sneeze at, so to speak. But we do wish breathless TV reporters would cease referring to it as the deadly virus, but that would be like asking them to stop referring to a horror smash rather than a sad everyday road accident.
While were on it, we also implore folk to stop hoarding toilet paper: after all, its the coronavirus, not the Caroma-virus.
Named after its crown-like shape but not the Royal Family per se, the common coronavirus is responsible for past pestilences including Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).
The virus may indeed fizzle out, as the earlier SARS plague did.
But for the time being, we need the best and brightest minds in the labs to come up with a treatment or more likely a vaccine.
There are some promising developments overseas, which your columnist will return to if he hasnt succumbed as well (he did shake hands with someone who went to a Chinese restaurant a couple of weeks back).
Among the local biotechs and we use the term loosely theres been no lack of endeavour in linking their efforts to the virus.
But to be fair, in some cases investors did it for them.
Take Biotron (ASX:BIT), which was an obvious subject of attention given the company is focused on developing antiviral drugs for HIV and hepatitis.
Biotron also has a program for pan respiratory viruses and mentioned corona in a June 2019 presentation. Some punters latched on to the fact that it wasnt referring to a 1970s Toyota or Mexican beer and the Hot Copper pundits were off and running.
Biotron CEO Dr Michelle Miller has been more circumspect.
Yes, she says, the company has some good advanced compounds to work on, but the reality is that theres nothing that would be ready to fight the current outbreak.
Dr Miller says while the companys work on pan respiratory viruses continues, theres not much to add at this stage.
Uscom (ASX:UCM) shares went on a run after the company reported increased orders for its haemodynamic monitoring devices in China.
Uscom stands for Ultra-Sonic Cardiac Output Monitors.
The Uscom 1A device is a non-invasive diagnostic that monitors cardiovascular functions, using Doppler ultrasound to detect abnormalities.
Chinese health authorities have recommended Uscom 1A as a monitoring device for severe coronavirus cases, while international guidelines also suggest using the device for paediatric sepsis.
Uscom reported that in the first five weeks of 2019, Chinese sales orders rose 124 per cent, from 17 units to 38 units.
Uscom chief Professor Rob Phillips says the company is well positioned with the virus, but notes that Uscom is not a coronavirus story as such: fatalities from cardiovascular pulmonary failure result from conditions such as pneumonia.
Happily for Uscom, the outbreak comes as the company hones-in on the Chinese market with a new direct sales model.
The molecular diagnostics house has a suite of approved tests that cover gastro-enteric strains, flavivirus/alphavirus, sexually-transmitted diseases and drum roll respiratory pathogens.
Genetic Signatures (ASX:GSS) Easyscreen tests cover pan coronaviruses, which until now has not been able to distinguish COVID-19 from, say, SARS.
But thats all changed, with the company introducing a supplementary test that does just that. Management is fast-tracking a validation program to obtain the data required for international regulatory approvals as rapidly as possible.
However, Genetic Signatures cant be accused of beating up its prospects: management says while the bug presents significant opportunities, the outcome of the emerging pandemic is uncertain.
While the early-stage coronavirus is detected by a blood test, chest x-rays are then used to gauge the severity of the illness and assess fluid in the lungs.
Micro-X (ASX:MX1) is all about developing lightweight and portable x-ray machines for medical applications, as well as other purposes such as defence and airports.
The companys first product, Carestream DRX Revolution Nano is approved in the US and Europe.
In mid-February the company said it had procured orders for $780,000 of machines from governments of two Asian countries, in response to the coronavirus threat. This week, another $1m of orders, all marked for urgent delivery, flooded in.
While these are terrible circumstances with the coronavirus spreading so quickly, we are pleased that our equipment will soon be able to assist medical teams with their responses in affected countries, Micro-X CEO Peter Rowland says.
Why waste a crisis? No fewer than four ASX stocks are capitalising on demand for hand and surface sanitisers to halt the bug in the first place.
Antimicrobial solutions house Zoono Group (ASX:ZNO) proclaims that its impressively-monikered Z-71 Microbe Shield, as used in its hand sanitisers, kills COVID-19 99.99 percent of the time.
Zoono is selling into China via a tie up with Eagle Health (ASX:EHH), which manufactures and distributes product into 26 provinces.
Aeris Environmental (ASX:AEI) goes one step better, claiming its Aeris Active product kills influenza and noroviruses in 99.999 percent of cases.
For those remaining 0.001 percent, bad luck and dont buy a lottery ticket.
Interestingly, that announcement did not refer specifically to the coronavirus. But earlier, Aeris announced the Singapore National Environment Agency had listed Aeris Active as one of the general disinfectants effective against the virus.
Meanwhile, fruit juice maker Food Revolution Group (ASX:FOD) has turned from filling its bottles with squeezed oranges to stuffing them with alcohol-based hand sanitiser under the Sanicare brand.
Who would have thought? The swift repositioning results from a 1,260sqm upgrade at the companys plant at Mill Park in outer Melbourne, which enables all sorts of gels, powders, oils and cosmetics to be bottled.
Mainstream sanitiser products such as Dettol and Lysol (made by multinational Reckitt and Benckiser) are flying off the shelves.
But is a good scrub with soap and water just as effective? Australian National University microbiologist Professor Peter Collignon opines theres little difference between hand washing and the alcohol-based sanitisers.
One is just more convenient than the other and contains alcohol, he says. You can put it in your pocket and dont have to be near a sink or basin to use it.
So whos actually tackling the disease? Offshore, theres a conga line of developers having a crack at a vaccine.
In Israel, scientists at the Galilee Research Institute claim to be on the cusp of finalising a product that is capable of getting regulatory assent within 90 days.
Thats what you call fast-track approval.
According to the Jerusalem Post, the same team of scientists has been developing a prophylactic against infectious bronchitis virus, which affects poultry.
The effectiveness of the vaccine has been proven in pre-clinical trials carried out at the countrys Veterinary Institute.
In the US, Gilead Sciences plans to recruit 1,000 patients with coronavirus for a clinical trial to test its experimental anti-viral drug remdesivir (as used to tackle Ebola virus).
With the backing of the World Health Organisation, the drug is also being trialed in China.
Maryland-based, Nasdaq-listed Novavax says it is cloning the coronavirus to develop a vaccine, in the same way it developed one for MERS in 2013.
Novavax is looking at several vaccine candidates for animals and hopes to find one for human testing by the end of May.
Our previous experience working with other coronaviruses, including both MERS and SARS, allowed us to mobilise quickly, Novavax CEO Stanley Eck said.
Fellow Nasdaq minnow Moderna has shipped an experimental vaccine to the National Institute of Allergy and Infectious Diseases for testing.
Backed by billionaire hedge fund founder Jim Simons, Long Island-based private outfit Codagenix expects to have a vaccine ready for animal testing in four to six weeks, with one suitable for testing about six weeks later.
The Codagenix know-how is based on recoding the genomes of viruses to render them harmless. The technique is not exactly unknown, as its been used to eradicate polio and small pox.
And who can forget Australias very own Relenza anti-influenza Biota, which became Alpharetta Georgias Nabi, changed its name to Aviragen and then was subsumed as a sub-division of San Franciscos Vaxart, popping its head above the parapet to also claim an anti-viral program for COVID-19.
The South China Morning Post reports that a 65-year-old woman on her COVID-19 deathbed walked out of Chinas Kunming Hospital after being given a stiff shot of mesenchymal stem cells (MSCs).
Two trials are also underway to test the therapy against pneumonia, at a Beijing Military Hospital and Zhongnan Hospital of Wuhan University (yep, in the coronavirus capital).
Could the excitement rub-off on our ASX-listed plays Mesoblast (ASX:MSB), Cynata Therapeutics (ASX:CYP), Orthocell (ASX:OCC) and Regeneus (ASX:RGS)?
Cynatas Dr Ross Macdonald says the reports look authentic; and he believes that MSCs could be an effective adjunct in managing patients with serious issues pertaining to COVID-19.
This is not because MSCs are inherently anti-viral or can act as a vaccine, but more because they have shown benefit in major pathologies associated with infection, he says.
Cynata, we stress, has not mentioned coronavirus in its dispatches and nor has any of the other non-China MSC plays or not yet anyway.
But still, what decent CEO would not give his company a plug?
The clear advantage of (Cynatas) Cymerus technology (is) the ability to make large quantities of consistent, robust MSCs without having to find gazillions of donors, Dr Macdonald says.
Your columnist stresses that the coronavirus influence on the sector is not all positive, with some biotechs likely to be affected by supply or other disruptions.
In mid-February, Cochlear (ASX:COH) quickly stepped off the mark by announcing its earnings for the 2019-20 year were likely to come in at $270-290m, compared with the previously guided $290-300m.
The reason is that hospitals in China and Hong Kong have delayed cochlear implant procedures to avoid the risk of infection.
The aforementioned Uscom notes that with labs preoccupied with the virus, short-term revenues are less predictable. In other words, the coronavirus is a distraction as well as an opportunity.
IDT Australias (ASX:IDT) Dr David Sparling told Biotech Daily that his company had no direct supply chain exposure to China at all, and was doubtful that even the companys gowns and protective gear had much to do with the Middle Kingdom.
Editors note: Dr. Tim Boreham, who wrote this article for Stockhead, is one of Australias best-known small cap analysts and business journalists.
If you throw enough money and resources at tackling a disease you will get a result, right?
Er, not quite: cures for well-researched ailments such as Alzheimers disease, multiple sclerosis and an array of cancers remain elusive.
But when youve got an ailment that is crippling the global economy, the imperative to find a solution is somewhat more intensive.
Our best guess is that like SARS and MERS, COVID-19 will hang around for years to come, but the ill-effects will be made more tolerable with an effective vaccine and/or improved immunity over time.
In other words, it will become just another disease in the pantheon of maladies blighting humanity.
In the race for a cure, Gileads Remdesivir looks interesting, given it has been used before.
As for the opportunists in the sanitiser game, the surge in demand means tangible revenue gains and good on them.
But lets be clear: theyre hardly breaking new ground technology-wise and their gains will only be short term as other suppliers enter the market.
As for a cure, or lack of one, we suggest that investors hedge their bets with an exposure to the funeral stocks Invocare (ASX:IVC) and Propel Funeral Partners (ASX:PFP).
After all, theyre the last people to let you down.
Stockheadcovers emerging ASX companies and investment opportunities. Get daily stock updates atStockhead.
See the article here:
The Aussie Biotech Companies Trying To Make A Buck From Coronavirus - D'Marge
3D beating heart tissue experiment heads to Space Station – UW Medicine Newsroom
By daniellenierenberg
Note to editors and reporters: Live coverage on NASA Television of the SpaceX CRS-20 cargo launch carrying this experiment is scheduled at 8:30 p.m. EST, 11:30 p.m. PST March 6 and will be replayed twice on March 7. Coverage of the rendezvous with the International Space Station will be at 5:30 a.m. EST Monday, March 8, with installation at 8:30 a.m. All times are subject to change due if weather or launch conditions are unfavorable
MEDIARESOURCES:
Downloads:
Soundbites
Web-embeddable video
Photos of tissue loading
Soundbite Log
Otherresources:
Youtube link
Space exploration can take a toll on the human heart. Astronauts are at risk for changes in their cardiac function and rhythm. To learn how microgravity and other physical forces in space exact their effects on heart muscle, a Tissue Chips in Space project has now been packed and is awaiting launch to the International Space Station.
The experimental equipment consists of small, compact devices, a little bit larger than cell phone cases. The holders contain a row of tiny, 3-D globs of beating heart tissue grown from pluripotent stem cells, generated from human adult cells. The heart muscle tissue is supported between two flexible pillars that allow it to contract freely, in contrast to the rigid constraints of a Petri dish.
The devices also house a novel invention from the University of Washington. It automatically senses and measures the contractions of the heart tissues, and reduces the amount of time the astronauts will need to spend conducting this study.
The flexible pillars contain tiny magnets, explained UW graduate student Ty Higashi, one of the inventors. When the muscle tissue contracts, the position of the embedded magnets changes, and the motion can be detected by a sensor, he said. That information is then sent down to a laboratory on Earth.
This model will recapitulate, on a miniature scale, what might be happening to the architecture and function of heart muscle cells and tissues in astronauts during a space mission.
The project head is Deok-Ho Kim, a professor in bioengineering, who recently joined the Johns Hopkins University faculty in Baltimore. He and co-investigator, Nathan Sniadecki, a professor in mechanical engineering, began this study two years at the UW Medicine Institute for Stem Cell and Regenerative Medicine (ISCRM). Jonathan Tsui, a postdoc in bioengineering, Ty Higashi, a graduate student in mechanical engineering , and other members of the UW project team, continue the cross-country collaboration in Seattle. The team is working with several NASA and National Institutes of Health groups, and researchers at other universities, on this effort.
Sniadecki said that each of the tissues heading to the International Space Center contain about a half million heart cells.
They act like a full tissue, he explained. They contract, they beat and you can actually see them physically shorten in the dish. Were actually able to see little heart beats from these tissues.
The SpaceX shuttle delivering this scientific payload is expected to leave from Cape Canaveral no earlier than 8:50 p.m. PST (11:50 p.m. EST) Friday, March 6. The exact departure schedule depends on the weather and other factors.
Once on board, the experiment will run for 30 days before being returned to Earth for further analysis. A related space-based experiment will follow skyward later, to see if medications or mechanical interventions can offset what the heart muscle endures during extended space missions.
The space program is looking at ways to travel longer and farther, Sniadecki said. To do so, they need to think about protecting their crews. Having treatments or drugs to protect astronauts during their travel would make long term space travel possible.
Guarding against cardiac problems would be especially critical during space travel at distances never attempted before, such as a mission to Mars, said Sniadecki. This opportunity to really kind of push the frontier for space travel is every engineers dream.
He added, We also hope to gather information that will help in preventing and treating heart muscle damage in people generally, as well as in understanding how aging changes heart muscle.
Microgravity is known to speed up aging, and likely influence other cell or tissue properties. Because aging is accelerated in space, studies on the International Space Station is a way to more quickly assess this process over weeks, instead of years.
I think the medicine side of it is extremely helpful on Earth, too, because what we discover could potentially lead to treatments for counteracting aging, Sniadecki said.
This space medicine research project is funded by the National Center for Advancing Translational Sciences and the National Institute of Biomedical Imaging and Bioengineering. This heart tissue study is part of the national Tissue Chips in Space program.
Here is the original post:
3D beating heart tissue experiment heads to Space Station - UW Medicine Newsroom
SpaceX Dragon to launch heart cell experiment and more to space station tonight – Space.com
By daniellenierenberg
CAPE CANAVERAL, Fla. SpaceX is preparing for its fifth launch of the year: a resupply mission to the International Space Station (ISS). The mission, which is scheduled to launch Friday (March 6) at 11:50 p.m. EST (0450 GMT on March 7), will bring a bevy of science material to the astronauts living and working in the orbiting laboratory.
This flight, dubbed CRS-20, marks the 20th and final mission for SpaceX under the company's first commercial cargo resupply services contract with NASA. Perched atop a Falcon 9 rocket will sit a cargo Dragon capsule filled with more than 4,300 lbs. (1,950 kilograms) of supplies, including more than 2,100 lbs. (950 kg) of science equipment.
The scientific cargo will support a host of experiments across Expeditions 62 and 63, focusing on a range of topics, from biological sciences (growing human heart cells in space), to water conservation methods, to particle-foam manufacturing and the addition of a new research platform on the ISS.
You can watch SpaceX's Dragon launch livehere on Space.com, courtesy of SpaceX, beginning at about 11:30 p.m. EST (0430 GMT), courtesy of NASA TV. You can alsowatch the launch directly from SpaceX here, beginning at 11:35 p.m. EST (0435 GMT).
Video: What's flying to the space station on SpaceX's CRS-20 mission?Related: SpaceX Dragon cargo ship launching tonight. How to watch live.
In its never-ending quest to create the best athletic shoe, Adidas has turned its sights to the International Space Station. The sportswear company has developed a performance midsole an additional shoe layer between the insole (next to your feet) and the sole (what touches the ground) that will enhance comfort.
To create its midsole, Adidas uses a process called particle foam molding, in which thousands of small pellets are blasted into a mold so they fuse together. To streamline the process and create the best shoe it can, Adidas is going to try this process in microgravity. The experiment, dubbed Adidas BOOST (Boost Orbital Operations on Spheroid Tessellation), will look at how the particles fuse together in space.
By removing gravity from the process, the team can take a closer look at individual pellet motion and location. The results of this investigation could show that the space station is a good platform for testing out new manufacturing methods and could lead to more-efficient means of packing and cushioning materials.
Related: Adidas launching new sneakers inspired by historic NASA spacesuits
Delta Faucet Co., a manufacturer of shower heads and other bathroom hardware, is launching a payload on CRS-20 that will seek to better understand how water droplets form. The company will use that knowledge to build a better shower head that lines up with Delta's ultimate goal: creating the sensation of increased pressure while using less water.
Conserving water is incredibly important, but one of the biggest drawbacks is that eco-friendly, low-flow shower heads do not perform as well as their less environmentally friendly counterparts. Users complain that the water pressure feels so low it's difficult to rinse off properly, which can result in longer showers and, ultimately, more water usage.
To help mitigate this issue, Delta has created a unique shower head, called the H2Okinetic, that controls the size and the speed of the water droplets with the help of an oscillating chip. That chip creates a better shower experience by breaking up the water flow into bigger droplets and shooting them out faster, giving the illusion of more water.
Related: Showering in space: Astronaut home video shows off 'hygiene corner'
"Water is a precious commodity," Garry Marty, principal engineer at Delta Faucet, said during a prelaunch briefing on Thursday (March 5). "We are trying to create a shower head to keep our customers happy while using less water."
He went on to explain that once the water leaves the pipes, it essentially doesn't have any pressure. What you're feeling are the droplets. With this new shower head, Delta Faucet is able to control the size and speed on each drop, revolutionizing the way a shower device delivers a shower.
"Lower-flow showers aren't really great to be under," Marty said. "But the more we understand, the more we can improve."
Marty added that, someday, humanity will be living on the moon or Mars and will need a way to take a shower. The lessons learned from this research go beyond conserving water and user experience, he said; it has implications for the space industry as well. But for now, the bigger concern is to better understand the fundamentals of water droplet formation.
Heart disease is the No. 1 cause of death in the U.S. A team of researchers from Emory University in Atlanta, led by Chunhui Xu, are sending an experiment up to the space station to explore how effectively stem cells can be turned into heart muscle cells.
The data collected could lead to new therapies and even speed up the development of new drugs that can better treat heart disease.
The microgravity environment found on the space station is known to have a profound effect on cell growth. Through this research, the team aims to understand the impact microgravity has on cardiac precursors (cardiac cells created from stem cells) and how effectively they produce cardiac muscle cells, called cardiomyocytes.
Related: Heart cells beat differently in microgravity, may benefit astronauts
Ground-based research shows that when cells are grown under simulated microgravity conditions, the production rate of cardiomyocytes is greater than if they were grown under the effects of gravity. By sending the experiment to the space station, Xu and her team will be able to determine if their results are accurate.
"Our goal is to help make stem cell-based therapy more readily available," Xu said during the briefing. "If successful, the demand for it will be tremendous, because heart disease is the No. 1 killer in America."
In order to have a successful therapy, Xu said that the team will need to produce a large number of high-quality cardiomyocytes. To do that, the researchers need to first understand the mechanisms behind cell transformation.
Bartolomeo is a new research platform that will be installed on the exterior of the space station. Placed outside the European Columbus module, this science balcony will host as many as 12 research experiments at one time.
Built by Airbus, the platform will enable researchers to conduct more experiments on the station's exterior. During a prelaunch briefing, NASA and Airbus explained that Bartolomeos potential uses include Earth observation, robotics, materials science and astrophysics.
"All of your [research] dreams can come true with Bartolomeo," said Andreas Schuette, program manager of Bartolomeo at Airbus.
And parking spots on the washing machine-sized platform are all-inclusive, which means that researchers can pay one price to launch, install, operate and even return to Earth. By working directly with agencies like NASA, ESA, and SpaceX, Airbus is able to offer a cost-effective means of conducting research on the space station.
The company is also working with the United Nations in an effort to entice those who wouldn't otherwise be able to afford to send payloads into space, Schuette told Space.com. The duo have teamed up with the United Nations Office for Outer Space (UNOOSA) to make that happen. (The agency works to make space more accessible.)
If all goes as scheduled, the Dragon will arrive at the International Space Station on Monday (March 9) at approximately 6 a.m. EDT (1000 GMT). From there, NASA astronauts Jessica Meir and Drew Morgan will use the station's Canadarm2 robotic arm to capture and attach the spacecraft, before beginning the unloading process.
Follow Amy Thompson on Twitter @astrogingersnap. Follow us on Twitter @Spacedotcom or Facebook.
Read more from the original source:
SpaceX Dragon to launch heart cell experiment and more to space station tonight - Space.com
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Provides An In-Depth Insight Of Sales Analysis-US STEM CELL, INC. – Fashion…
By daniellenierenberg
This new report by Eon Market Research, titled Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Research Report, 2015 2025 offers a comprehensive analysis of Autologous Stem Cell and Non-Stem Cell Based Therapies industry at a global as well as regional and country level. Key facts analyzed in this report include the Autologous Stem Cell and Non-Stem Cell Based Therapies market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2020-2025. This report primarily focuses on the study of the competitive landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors in global Autologous Stem Cell and Non-Stem Cell Based Therapies market.
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market presents market size in terms of volume and value (or whichever applicable) for the entire forecast period and also offers CAGR for the forecast period under consideration.
Grab a sample of this report and get instant 10% discount @ https://www.eonmarketresearch.com/sample/55837
**If you have any special requirements, please let us know and we will offer you the report as you want.**
Key trends analyzed for the prospective readers of this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include major demand drivers, restraints and key opportunities prevailing in the industry. Certain high-level analysis of Autologous Stem Cell and Non-Stem Cell Based Therapies market such as value chain analysis, Porters five forces analysis, SWOT analysis, and market attractiveness analysis to cover all the circumstances affecting this Autologous Stem Cell and Non-Stem Cell Based Therapies industry is also covered in this report. Portfolio analysis helps to understand the product mix of leading companies in the Autologous Stem Cell and Non-Stem Cell Based Therapies industry.
This report focuses on top manufacturers in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market, with revenue production, sales, gross margin, and market share for each manufacturer, covering
U.S. STEM CELL, INC.Brainstorm Cell TherapeuticsCytoriDendreon CorporationFibrocellLion BiotechnologiesCaladrius BiosciencesOpexa TherapeuticsOrgenesisRegenexxGenzymeAntriaRegeneusMesoblastPluristem Therapeutics IncTigenixMed cell EuropeHolostemMiltenyi Biotec
Place An Inquiry Before Buying @ https://www.eonmarketresearch.com/enquiry/55837
Consumption, production, capacity, market share, growth rate, and prices are included for each product type segment of Autologous Stem Cell and Non-Stem Cell Based Therapies market
Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells
Consumption, market share and growth rate for each application segment of Autologous Stem Cell and Non-Stem Cell Based Therapies market
Neurodegenerative DisordersAutoimmune DiseasesCancer and TumorsCardiovascular Diseases
The Autologous Stem Cell and Non-Stem Cell Based Therapies market report presents all-inclusive information on raw materials suppliers, equipment suppliers, manufacturing cost, capacity, production, profit margin, capacity utilization rate, etc. The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market report also covers a systematic geographical analysis.
Key regions analyzed in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market include; North America, Latin America, Europe, Asia Pacific, and Middle East Africa. The country-level analysis included for U.S., UK, France, Germany, Russia, China, Japan, India, and Brazil. The Autologous Stem Cell and Non-Stem Cell Based Therapies industry report provides detailed bifurcation of each segment on global, regional and country level. In a word, the Autologous Stem Cell and Non-Stem Cell Based Therapies market report provides major statistics on the state of the industry and is a valuable source of direction and control for companies and individuals interested in the market.
About Us-
Eon Market Research is one of the unique research reports and service providers that help to find out the different research reports of Chemical, food and beverages, consumer goods, Energy, Medical devices and Pharmaceutical and Health Care.
Contact Us:
Eon Market ResearchPhone: +1 703 879 7090Email: sales@eonmarketresearch.com
Follow this link:
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Provides An In-Depth Insight Of Sales Analysis-US STEM CELL, INC. - Fashion...
With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis – P&T…
By daniellenierenberg
The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism
LONDON, March 4, 2020 /PRNewswire/ -- Roots Analysishas announced the addition of "Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))" report to its list of offerings.
There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.
To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link
Key Market Insights
Over 280 stem cell therapies are under development, most of which are allogeneic products
More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.
70% of pipeline candidates are based on mesenchymal stem cells
It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.
Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions
Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies
Over 1,500 grants were awarded for stem cell research, since 2015
More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.
Outsourcing has become indispensable to R&D and manufacturing activity in this domain
Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.
North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030
The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.
To request a sample copy / brochure of this report, please visit this link
Key Questions Answered
The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:
The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.htmlor email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:Gaurav Chaudhary+1(415)800-3415+44(122)391-1091Gaurav.Chaudhary@rootsanalysis.com
Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg
Read the rest here:
With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis - P&T...
Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS – Newswise
By daniellenierenberg
Newswise Launching no earlier than March 6 at 11:50 PM EST, the Johns Hopkins University will send heart muscle tissues, contained in a specially-designed tissue chip the size of a small cellphone, up to the microgravity environment of the International Space Station (ISS) for one month of observation.
The project, led by Deok-Ho Kim, an Associate Professor of Biomedical Engineering and Medicine at The Johns Hopkins University and the projects principal investigator, will hopefully shed light on the aging process and adult heart health, and facilitate the development of treatments for heart muscle diseases.
Scientists already know that humans exposed to space experience changes similar to accelerated aging, so we hope the results can help us better understand and someday counteract the aging process, says Kim.
The researchers also hope the study will demystify why astronauts in space have reduced heart function and are more prone to serious irregular heartbeat; these results could help protect astronauts hearts on long missions in the future, as well as provide information on how to combat heart disease.
Kim and his team used human induced pluripotent stem cells to grow cardiomyocytes, or heart muscle cells, in a bioengineered, miniaturized tissue chip that mimics the function of the adult human heart. While other researchers have studied stem cell-derived heart muscle cells in space before, these studies relied on cells cultured on 2D surfaces, or flat planes, that arent representative of how cells exist and behave in the body, and are therefore underdeveloped compared to their counterparts in adult humans.
The teams tissue platform gives the advantage of the cells residing in a 3D environment, which will allow for better imitation of how cell signals and actions develop as they would in the human body. This 3D environment is possible thanks to a new scaffold biomaterial, or support structure which holds the tissues together, that accelerates development of the heart muscle cells within. This will allow the scientists to collect data useful for understanding the adult human body. Scientists could someday use this data and platform to develop new drugs, among many other applications.
Using a motion sensor magnet setup, the team will receive real-time measurements of how the tissues on the ISS beat. After about one month in space, the tissues will return to Earth and will be analyzed for any differences in gene expression and contraction caused by the extended stay in microgravity. Some of these tissues will be cultured for an additional week on Earth for the researchers to examine any recovery effects. The team will also have identical heart tissues on Earth at the University of Washington to serve as controls.
We hope that this project will give us meaningful data that we can use to understand the hearts structure and how it functions, so that we can improve the health of both astronauts and those down here on Earth, says Kim.
"The entire team is excited to see the results we get from this experiment. If successful, we will embark on the second phase of the study where tissues will be sent up to the ISS once again in two years, but this time, we will be able to test a variety of drugs to see which ones will best ameliorate the potentially harmful effects of microgravity on cardiac function," says Jonathan Tsui, a postdoctoral fellow in the Department of Biomedical Engineering at The Johns Hopkins University and a member of Kims lab.
This project is funded by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) as part of the Tissue Chips in Space initiative in collaboration with the ISS U.S. National Laboratory.
Collaborators on this project include Eun Hyun Ahn of The Johns Hopkins University; Nathan Sniadecki and Alec Smith of The University of Washington; Peter Lee of Ohio State University; and Stefanie Countryman of Bioserve Space Technologies at the University of Colorado Boulder. For space flight the team has worked with BioServe Space Technologies to translate the ground platform into a space flight certified system.
Link:
Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS - Newswise
Regenerative Medicine Market Analysis Growth Demand, Key Players, Share Size, and Forecast To 2025 – Monroe Scoop
By daniellenierenberg
Regenerative Medicine Market: Snapshot
Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.
Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889
Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.
There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.
Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.
Global Regenerative Medicine Market: Overview
The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.
Global Regenerative Medicine Market: Key Trends
The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.
On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.
Global Regenerative Medicine Market: Market Potential
The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.
Global Regenerative Medicine Market: Regional Outlook
In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.
Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.
Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889
Global Regenerative Medicine Market: Competitive Analysis
The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.
Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.
About TMR Research:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
The rest is here:
Regenerative Medicine Market Analysis Growth Demand, Key Players, Share Size, and Forecast To 2025 - Monroe Scoop
Techshots New Projects Will be on the Next SpaceX Mission Launch – 3DPrint.com
By daniellenierenberg
2020 is already promising to be a fantastic year for space exploration. The next generation of Artemis explorers can begin applying for the program that will be journeying to the Moon, Mars and beyond; the James Webb Space Telescope is ready to test key deployments made in space, and even the Orion spacecraft that will blast off to the Moon during Artemis missions has successfully passed its final tests. Furthermore, NASA and commercial space companies prepare for the colonization of orbit, rockets are taking payloads to the International Space Station (ISS) very often and 3D bioprinting is becoming an attractive and useful method to carry out experiments. The next one up is SpaceX mission CRS-20. Scheduled to launch at 11:50 PM Eastern Time (EST) on March 6 from Floridas Cape Canaveral Air Force Station, the unpiloted cargo spacecraft is expected to arrive at the orbiting laboratory two days later with three Techshot-managed research campaigns.
The Indiana-based commercial research company is sending equipment and samples supporting plant, heart and cartilage research for NASA, Emory University and the Uniformed Services University of the Health Sciences (USU) to the ISS. According to the company, astronauts onboard the station will use Techshots 3D BioFabrication Facility (BFF) mounted inside the ISS U.S. National Laboratory (ISS National Lab) since last summer to manufacture human knee menisci for the 4-Dimensional Bioprinting, Biofabrication, and Biomanufacturing, or 4D Bio3program. Based at USU, 4D Bio3 is a collaboration between the USU and The Geneva Foundation, a non-profit organization that advances military medical research.
Funded by the U.S. Defense Health Program and managed by the Geneva Foundation, 4D Bio3promotes the development and application of advanced bioprinting, biofabrication, and biomanufacturing technologies for research pursuant to U.S. Department of Defense priorities and ultimately for translation to clinical medical defense care and training solutions.
This is our most diverse manifest to date, said Techshot President and CEO, John Vellinger. Throughout March well be conducting three major investigations in space for three customers using three very different Techshot-built research devices. Its going to be a busy month, but were excited to see the results.
Techshot owns BFF and the company built it at a cost of approximately seven million dollars. The starting point was an nScrypt printer, which now is highly modified by Techshot for use inside the ISS. In that relationship, Techshot handles all the space bioprinting, while nScrypt handles all the Earth-based bioprinting.
This first experiment for 4D Bio3 next month will be used as a test of the materials and the processes required to print a meniscus in space. Techshot engineers will upload a design file to BFF from the companys Payload Operations Control Center in Greenville, Indiana, and evaluate its success via real-time video from inside the unit. A second meniscus print will take place in BFF early next year and the item will then be returned to Earth for extensive testing and comparison to the nScrypt Earth-printed items. Last year nScrypt printed the same thing at a U.S. military base in Africa with their own printer.
Vincent B.Ho, Director of 4D Bio3 and professor and chair of radiology at USU said that meniscal injuries are one of the most commonly treated orthopedic injuries, and have a much higher incidence in military service membersreported to be almost 10 times that of the civilian population. We successfully biofabricated 3D human medial and lateral menisci in a pilot study performed in Africa last summer and anticipate learning valuable lessons on the challenges and benefits of biofabrication in microgravity by performing a similar experiment on the space station.
Besides BFF, there are four other Techshot owned and operated research machines inside the ISS today. Only the BFF is a bioprinter. The others are an X-ray machine for mice, two identical units called the Techshot Multi-use Variable-gravity Platform (MVP), and one called the ADvanced Space Experiment Processor (ADSEP), which is where cells printed in the BFF go to become conditioned and cultured into the tissue. The company has agreements with NASA and the ISS National Lab that permit Techshot to operate a commercial business in space. This is part of NASAs objective to make orbit more commercial, providing access to space for nearly anyone.
Another complex Techshot-managed experiment launching onboard SpaceX CRS-20 will test whether a heart-specific stem cell, called a cardiac progenitor, multiplies better in space and if more of them become heart muscle cells known as cardiomyocytes. This is part of Chunhui Xu, an associate professor in the department of pediatrics at the Emory University School of Medicine who studies heart cells, research that aims to improve treatments for congenital heart disorders and better the hearts ability to regenerate after injuries.
Preparing the experiments: under the vent hood, Biomedical Engineer Jordan Fite adds media to bags and fluid loops that will be used in the experiment in space (Image: Techshot)
Techshot explained that human cardiac tissues cant repair themselves once damaged from disease, due to this, repairing a failing heart by cell therapy requires a large number of cardiomyocytes, which can be converted from stem cells cultured in two dimensions in Earth-based laboratories. Without the pull of gravity, it is expected that culturing in three dimensions in space, inside specialized Techshot cell culture experiment modules, will increase the yield of high-quality heart muscle cells. The company expects that learning more about why this happens could lead to new strategies for reproducing the same results on a much larger scale on Earth, lowering costs and enabling more patients to receive needed cardiac cell therapies.
Astronaut handling Techshots BFF (Image: Techshot/NASA)
It is expected that once the cargo spacecraft reaches the station, the 12 Techshot experiment modules will be removed from the spacecraft and inserted by the crew into the companys Multi-use Variable-gravity Platform (MVP) unit number two mounted in the Japanese space laboratory known as Kibo.
We are thankful for Techshots engineers who designed the Multi-use Variable-gravity Platform hardware and will help us maintain constant communication with the astronauts during the flight operation. Their professionalism and collaboration with our team have contributed tremendously toward our overall research efforts, said Ho.
Besides the materials for the BFF meniscus print, SpaceX CRS-20 will also carry 12 Passive Orbital Nutrient Delivery System, or PONDS, plant growth devices that Techshot co-developed with Tupperware Brands, and that was first prototyped by NASA Kennedy Space Center. According to company officials, they will be growing red romaine lettuce inthe devices, installed inside two of the space stations identical plant growth chambers each called Veggie. The PONDS units are being tested in two different configurations, each representing approaches refined from two previous flight tests. For this demonstration, lettuce is expected to grow in space for 21 days. Besides the hardware built and own, Techshot also manages the space stations most complex greenhouse, called the Advanced Plant Habitat, and it manages two on-orbit research furnaces called PFMI and SUBSA.
Techshot has been working hard to get samples ready in a lab at the Space Station Processing Facility at NASAs Kennedy Space Center.
Product assurance associate Keri Roeder, program manager Nathan Thomas and mechanical engineer Grant Vellinger prepared samples for Techshot customer Emory University (Image: Techshot)
Founded more than 30 years ago, Techshot operates its own commercial research equipment in space and serves as the manager of three NASA-owned ISS payloads. The company is also working on other space 3D printing technologies. Last fall they tested a laser-based 3D metal printer in zero gravity inside an aircraft performing parabolic arcs over the Gulf of Mexico (sometimes unofficially nicknamed the vomit comet). However, officials suggest that this technology is still at least a couple of years from Techshot launching it to the space station.
NASA and dozens of companies continue to work together to develop the means for astronauts and space explorers to endure life in orbit, the Moon and other planets. This vision is enthralling for anyone who ever dreamed of going to space, even hopeful of the next generations that will be able to experience space travel and conduct research work in microgravity. Perhaps we are too hopeful of the future, but with so much going on, its difficult not to be.
The launch on Friday will be the last SpaceX launch under the current NASA CRS-1 contract, yet SpaceX will continue performing resupply missions under a new CRS-2 contract beginning with the next scheduled resupply mission in August this year. To watch the launch, which is scheduled to take place at 11:50 p.m. EST on Friday, March 6, and capture of the spacecrafts arrival at the ISS, you can tune into NASA TV using the video below:
Visit link:
Techshots New Projects Will be on the Next SpaceX Mission Launch - 3DPrint.com